-
Morgan Stanley Finds A Few Reasons To Double Upgrade Baxter
Wednesday, January 2, 2019 - 3:34pm | 375Read More...Shares of Baxter International Inc (NYSE: BAX) are trading at a valuation that implies low growth, but Morgan Stanley sees three catalysts ahead that will likely result in top-and-bottom line acceleration into 2020. The Analyst Morgan Stanley's David Lewis upgraded Baxter from Underweight to...
-
Analyst Upgrades Fitbit Ahead Of Push Into MedTech Space
Friday, October 12, 2018 - 1:01pm | 355Read More...Fitness tracker Fitbit Inc (NYSE: FIT)'s announcement it will enter the health care and medical technology space is a bullish catalyst for the stock. The Analyst Wedbush analysts led by Michael Pachter upgraded Fitbit from Neutral to Outperform with an unchanged $6.50 price target. The...
-
Neuronetics Wins A Sell-Side Bull With Pill-Free Depression Treatment
Monday, July 23, 2018 - 4:58pm | 320Read More...Neuronetics Inc (NASDAQ: STIM) boasts a therapy that addresses a pressing medical need, according to JMP Securities. The Analyst Analyst David Turkaly initiated coverage of Neuronetics with an Outperform rating and $36 price target. The Thesis For patients who have failed one of...
-
Tactile Systems' Valuation Is 'Getting Stretched,' BTIG Says In Downgrade
Monday, June 4, 2018 - 9:39am | 378Read More...After doubling in value over the past seven months alone, shares of Tactile Systems Technology Inc (NASDAQ: TCMD) are trading at a "stretched" valuation despite expectations for continued growth ahead, according to BTIG. The Analyst BTIG's Sean Lavin downgraded Tactile Systems...
-
Inspire Medical Systems Goes Public
Thursday, May 3, 2018 - 3:53pm | 258Read More...The medical technology company Inspire Medical Systems, Inc. (NYSE: INSP) went public Thursday on the New York Stock Exchange. What Happened The company issued 6.75 million shares priced at $16 each. Initially, it had plans to file for 5 million shares. Inspire Medical Systems was founded in 2017...
-
IRhythm Technologies Is Breaking Ground In Cardiac Monitoring, Says New Sell-Side Bull
Tuesday, March 6, 2018 - 1:43pm | 370Read More...Medtech name IRhythm Technologies Inc (NASDAQ: IRTC) is redefining how cardiac arrhythmias are monitored, which makes the stock an attractive buy, according to BMO Capital Markets. The Analyst BMO analyst Joanne Wuensch initiated coverage of iRhythm Technologies' stock with an...
-
6 Reasons Why William Blair Turned Bullish On Abbot Laboratories
Thursday, January 25, 2018 - 4:52pm | 426Read More...Abbott Laboratories (NYSE: ABT) reported fourth-quarter results that were highlighted by a top- and bottom-line beat and a guidance range for the first quarter that came in ahead of the consensus estimate. The Analyst William Blair's Margaret Kaczor upgraded Abbott Laboratories...
-
JPMorgan Diagnoses The MedTech Space: Stock Picks And Pans
Tuesday, January 2, 2018 - 4:45pm | 377Read More...The medical technology space for the most part benefited throughout 2017 and heading into 2018 some Wall Street analysts remain bullish. The Analyst JPMorgan's Michael Weinstein. The Thesis 2017 was a positive year for the MedTech space and was able to overcome multiple challenges,...
-
Abbott Laboratories Makes BMO Capital's Top Picks List
Tuesday, December 12, 2017 - 1:34pm | 454Read More...Abbott Laboratories (NYSE: ABT) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch upgraded Abbott's stock rating from Market Perform to Outperform with a price target...
-
Patterson's Growth, Market Share At Risk In The Years Ahead
Thursday, July 6, 2017 - 2:32pm | 462Read More...Patterson Companies, Inc. (NASDAQ: PDCO), a distributor of consumable dental products and other services, is expected to see pressure in the coming years to its growth profile and market share take, according to analysts at Stifel. Stifel's Jonathan Block downgrades Patterson's stock rating from...
-
Globus Medical Stands On The Brink Of Inflection; Leerink Upgrades
Wednesday, April 12, 2017 - 2:47pm | 373Read More...Considering Globus Medical Inc (NYSE: GMED) on the verge of significant revenue growth acceleration, Leerink Swann upgraded the musculoskeletal medical device company to Outperform and increased its price target from $29 to $40. The firm has been anticipating the ratings change since it downgraded...
-
Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive
Wednesday, June 3, 2015 - 3:27pm | 397Read More...In a report published Tuesday, Goldman Sachs analyst David Roman revisited the small-cap names under his coverage and noted that he is sticking with his view that product cycles and U.S. cyclical exposure (hospital capex/utilization) remain the "most prominent" drivers of upside....
-
Oppenheimer Highlights MDT In Its Ongoing Cash Piece
Monday, March 14, 2011 - 9:12am | 135Read More...In the second installment of Oppenheimer's ‘Following the Cash' report, “we check in on the balance sheet and cash flow generation of the large cap medical device group through year-end 2010.” “As we looked through the 4Q comments of the major medical device companies, cash was indeed a theme,”...
